ARK Investment Management LLC Boosts Stock Holdings in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS)

Key Points

• ARK Investment Management LLC increased its stake in COMPASS Pathways by 4.0%, owning 1,804,803 shares worth approximately $5.16 million after purchasing an additional 68,601 shares in the first quarter.
• COMPASS Pathways has received mixed ratings from analysts, with targets ranging from $6.00 to $45.00, leading to a consensus rating of "Moderate Buy" with a price target of $17.00.
• The stock opened at $4.33 and has a market capitalization of $405.11 million, with a 12-month high of $8.54 and a low of $2.25.

ARK Investment Management LLC boosted its holdings in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 4.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,804,803 shares of the company's stock after acquiring an additional 68,601 shares during the quarter. ARK Investment Management LLC owned 1.95% of COMPASS Pathways worth $5,162,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Affinity Asset Advisors LLC boosted its position in COMPASS Pathways by 183.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company's stock worth $3,215,000 after purchasing an additional 550,000 shares during the period. Jane Street Group LLC boosted its holdings in shares of COMPASS Pathways by 72.7% during the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock valued at $196,000 after buying an additional 21,815 shares in the last quarter. Barclays PLC boosted its stake in COMPASS Pathways by 2.1% in the 4th quarter. Barclays PLC now owns 419,194 shares of the company's stock worth $1,585,000 after purchasing an additional 8,718 shares in the last quarter. GAMMA Investing LLC raised its position in COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after buying an additional 5,003 shares during the last quarter. Finally, Tang Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $3,780,000. 46.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CMPS has been the subject of a number of research reports. Evercore ISI reiterated an "in-line" rating and set a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of COMPASS Pathways in a report on Tuesday, July 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $17.00.

COMPASS Pathways Stock Down 0.6%

Shares of COMPASS Pathways stock traded down $0.03 during trading hours on Wednesday, reaching $4.27. 590,610 shares of the company's stock were exchanged, compared to its average volume of 1,797,094. The stock has a market cap of $399.03 million, a P/E ratio of -2.15 and a beta of 2.12. The company has a current ratio of 10.18, a quick ratio of 10.18 and a debt-to-equity ratio of 0.11. COMPASS Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $8.54. The company has a 50 day moving average of $4.00 and a two-hundred day moving average of $3.78.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03. On average, sell-side analysts forecast that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.